Últimas noticias sobre Oruka Therapeutics (NASDAQ:ORKA) Bolsa

Oruka Therapeutics

Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.

APLD

AZTR

CRKN

CVGW

GCTK

GLAC

HSDT

LFWD

MASS

ORKA

QBTS

QUBT

RIME

SGBX

VMAR

VRME

Descubre las acciones ganadoras y perdedoras en el premercado, con Vision Marine liderando un aumento del 45%.

Las acciones de Vision Marine (VMAR) se disparan un 45%; 20 acciones que se están moviendo en premercado

Oruka Therapeutics Inc

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: S&P Rises Following Dec. CPI And Strong Bank Earnings, Israel And Hamas Reach Hostage And Ceasefire Agreement

Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares are trading higher by 0.99% to $116.35 during Wednesday&#8217;s session amid the broader market&#8217;s positive reaction to <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43003047/stocks-rise-on-core-inflation-slowdown-banks-rally-after-strong-q4-earnings-treasury-yields-plummet">December inflation data</a>.
The report showing slowing underlying price pressures is a positive signal for the broader economy, fueling investor optimism that the Federal Reserve may soon implement further rate cuts. 
What Else: For Marvell, <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43001512/inflation-rises-to-29-in-december-core-slows-yet-rising-energy-costs-put-feds-target-at-risk">lower interest rates</a> reduce the cost of capital and could help spur investment in data centers, cloud computing, and 5G technologies—key areas in which Marvell plays a crucial role. 
As a semiconductor supplier that powers these industries, Marvell stands to gain from increased demand as businesses expand their infrastructure in response to favorable economic conditions.
Additionally, with semiconductor stocks often benefiting from a lower cost of financing, Marvell could see further upside as the probability of rate cuts in 2025 rises.
Read Also: <a href="https://www.benzinga.com/general/market-summary/25/01/42996490/nordea-parisi-gray-graypoint-load-up-on-marvell-technology-shares-iaim-dilutes-98-in-q4-heres-what-mrvls-technical-analysis-says">Nordea, Parisi Gray, Graypoint Load Up On Marvell Technology Shares, IAIM Dilutes 98% In Q4: Here&#8217;s What MRVL&#8217;s Technical Analysis Says</a>
Investors can gain exposure to&nbsp;MRVL by&nbsp;investing&nbsp;in the VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>).
<h2 class="wp-block-heading">How To Buy MRVL Stock</h2>
By now you're likely curious about how to participate in the market for Marvell Technology &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Marvell Technology, which is trading at $116.72 as of publishing time, $100 would buy you 0.86 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MRVL has a 52-week high of $126.12 and a 52-week low of $53.19.

News

MRVL

What's Going On With Marvell Technology (MRVL) Stock?

Defense stocks are moving slightly lower Wednesday after Israel and Hamas verbally agreed on a <a href="https://www.benzinga.com/25/01/43011383/israel-gaza-ceasefire-hostage-exchange">ceasefire in Gaza</a>.
What Happened: Hamas accepted a draft agreement on Wednesday for a ceasefire in Gaza that includes the release of several hostages, according to <a href="https://www.benzinga.com/25/01/43011383/israel-gaza-ceasefire-hostage-exchange">multiple reports</a>. 
The agreement follows months of negotiations and paves the way for a potential end to the ongoing war in the Middle East that began about 15 months ago. The verbal agreement also comes just days before President-elect Donald Trump&#8217;s inauguration. 
&#8220;We have a deal for the hostages in the Middle East. They will be released shortly. Thank you!&#8221; Trump&nbsp;said in a post on Truth Social.
The deal reportedly includes a six-week ceasefire and the release of 33 Israeli hostages in exchange for the release of Palestinian prisoners. Israel still needs to ratify the deal, but a vote is expected by Thursday. 
Related Link: <a href="https://www.benzinga.com/25/01/43011383/israel-gaza-ceasefire-hostage-exchange">Israel, Hamas Agree To Cease-Fire Deal With Hostage Exchange: What You Need To Know</a>
Defense stocks including Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Northrop Grumman Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) and RTX Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) moved lower as the ceasefire reports surfaced despite a strong session from broader indices. The Global X Funds Global X Defense Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHLD#NYSE">SHLD</a>) and the SPDR S&amp;P Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XAR#NYSE">XAR</a>) also pulled back from highs on the news. 
At the time of writing, Lockheed Martin shares were down about 0.7%, while Northrop Grumman and RTX shares were down about 0.8%. It&#8217;s worth noting that the SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 1.77% at last check.
Defense stocks have benefitted from the ongoing war in the Middle East with the Global X Funds Defense ETF having gained more than 35% over the past year, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Defense stocks tend to rally in periods of elevated conflict given their heavy reliance on government contracts. 
Energy stocks including BP P.L.C (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>), Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) also pulled back slightly on the ceasefire news, but bounced back pretty quickly. 
The United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) hit new 52-week highs on Wednesday on continued momentum from last week after the U.S. announced its most extensive sanctions on Russian oil exports to date.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42948649/goldman-sachs-warns-of-90-oil-risk-trump-may-not-ease-sanctions-once-he-takes-office">Oil Could Hit $90, Goldman Sachs Says: &#8216;Trump May Not Ease Sanctions&#8217; On Russia</a></li>
</ul>
Photo: courtesy of Lockheed Martin.

Global

Movers

SHLD

Defense Stocks Fall On Gaza Ceasefire While Broader Market Rallies: What's Going On?

Denali Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) CEO Ryan Watts presented at the J.P. Morgan Healthcare Conference.&nbsp;
The presentation primarily focused on&nbsp;the company&#8217;s blood-brain-barrier (BBB) crossing platform technology and the pipeline, including tividenofusp alfa (tivi, DNL310) in Hunter syndrome and DNL126 in Sanfilippo syndrome Type A,&nbsp;as well as ATV:Abeta approach in Alzheimer&#8217;s disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42856965/denali-therapeutics-amyotrophic-lateral-sclerosis-misses-pivotal-trial-but-analyst-says-it-was-expected" rel="noreferrer noopener">Denali Therapeutics&#8217; Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected</a>
JP Morgan notes that the management believes each TV franchise has the potential to generate over $3 billion in value.
The analyst views Denali Therapeutics as being in the early stages of unlocking the full potential of its BBB TV platform across various applications, maintaining the stock&#8217;s Overweight rating.
Ahead of the conference, DNL310 received Breakthrough Therapy Designation in Hunter Syndrome and is on track to file a BLA for accelerated approval in early 2025. Based on this timeline, JP Morgan expects a potential late-2025/early 2026 launch.
<ul>
<li>The company is gearing up for commercialization and product launch, focusing initially on the U.S. market. Management estimates there are approximately 400-500 patients in the U.S.</li>
<li>Meanwhile, the Phase 2/3 COMPASS trial has completed enrollment for neuronopathic participants in cohort A. Both study cohorts are expected to have simultaneous results, but no timeline for the readout has been provided. Globally, management estimates around 2,000 patients.</li>
</ul>
On DNL126, the management did not share detailed data but emphasized promising results from the Phase 1/2 trial in Sanfilippo syndrome Type A.
These include DNL126&#8217;s ability to normalize CSF HS levels. Building on these findings and insights from DNL310, the company is working to speed up DNL126&#8217;s development timeline.
To support this, they expanded the Phase I/II trial from two to five cohorts, aiming for a faster approval pathway. Management estimates a global patient population of over 1,500.
JP Morgan also notes that Denali Therapeutics has a manufacturing facility. While it won&#8217;t be used for the commercial launch of Tivi in Hunter syndrome, it is expected to support the company&#8217;s other programs.
As of September 30, 2024, cash, cash equivalents, and marketable securities were approximately $1.28 billion. Denali anticipates its cash runway <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42942702/denali-therapeutics-announces-key-anticipated-2025-milestones-and-priorities-to-further-advance-it" rel="noreferrer noopener">will extend into 2028</a>.
Price Action: DNLI stock is up 14.60% at $21.48 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43010888/ftc-says-unitedhealth-cvs-cigna-make-billions-via-pbms-on-specialty-drugs" target="_blank" rel="noreferrer noopener">FTC Says UnitedHealth, CVS, Cigna Make Billions Via PBMs On Specialty Drugs</a></li>
</ul>

Analyst Color

Biotech

Health Care

Analyst Ratings

Trading Ideas

DNLI

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Contracts

LUNR

Intuitive Machines Mentioned As Part of $4.82B Contract From NASA For 'Near Space Network Services - Contract Award'

Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) President &amp; CEO Jay Backstrom presented at the J.P. Morgan <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42885696/scholar-rock-highlights-2025-strategic-priorities" rel="noreferrer noopener">Healthcare Conference</a>.
The discussions mainly focused on apitegromab for spinal muscular atrophy (SMA), including its label if approved. They also covered commercial aspects such as the prevalence of SMA, the potential market, and factors influencing its adoption.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41208885/scholar-rocks-muscle-wasting-drug-excels-in-pivotal-trial-plans-fda-submission-next-year" rel="noreferrer noopener">Scholar Rock&#8217;s Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year</a>
<ul>
<li>Regarding apitegromab in SMA, the company plans to submit U.S. and European marketing applications in the first quarter of 2025, aiming for a potential U.S. launch in the fourth quarter of 2025, followed by a European launch.</li>
<li>Detailed results from the phase 3 SAPPHIRE trial, which involves patients with non-ambulatory type 2/3 SMA treated with Spinraza (nusinersen) or Evrysdi (risdiplam), are expected to be presented at medical meetings in 2025.</li>
<li>By mid-2025, the company aims to start the phase 2 OPAL trial, focusing on patients under 2 years old to understand how the drug behaves and guide dosing.</li>
<li>Regarding the addressable market, the company estimates the current SMA market at around $4.5 billion across three SMN-targeted therapies, mainly in the 2-21-year-old age group. They now expect apitegromab to reach over $2 billion in global revenue, an increase from previous estimates of $1 billion, driven by strong data and a favorable competitive landscape.</li>
</ul>
The analyst also discussed the upcoming results from the Phase 2 EMBRAZE trial, which is evaluating apitegromab combined with tirzepatide or semaglutide in adults who are overweight or obese. The data is expected in the second quarter of 2025.
JP Morgan remains positive on Scholar Rock (<a href="https://www.benzinga.com/quote/SRRK/analyst-ratings" target="_blank" rel="noreferrer noopener">Overweight rating</a>), as the recent SAPPHIRE trial results have unlocked strong growth potential for apitegromab in spinal muscular atrophy. The company could enter the commercial stage by 2025, and the analyst expects a strong product launch.
The analyst also sees potential for further value in the stock if the cardiometabolic data shows positive results, with initial data expected in the second quarter of 2025.
Price Action: SRRK stock is up 4.89% at $43.56 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43010389/why-nxp-semiconductors-stock-is-seeing-blue-skies-on-wednesday" target="_blank" rel="noreferrer noopener">NXP Semiconductors Secures $1 Billion European Investment Bank Loan For R&amp;D Expansion: Details</a></li>
</ul>
Photo via Shutterstock.

Equities

Reiteration

SRRK

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Just before the JP Morgan healthcare conference, Eli Lilly and Co&nbsp;(NYSE:&nbsp;LLY) announced that it expects 2024 full-year worldwide revenue to be approximately&nbsp;$45.0 billion, representing a 32% growth compared to the previous year versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42976923/eli-lilly-expects-around-55-billion-sales-from-weight-lossdiabetes-drugs-with-overall-topline-growth-of-32-issues-2025-forecast" rel="noreferrer noopener">consensus of $45.50 billion</a>.
The company's expected 2024 revenue is&nbsp;$400 million, or about 3%, below the guidance range issued during the&nbsp;third-quarter earnings. The guidance includes approximately&nbsp;$3.5 billion&nbsp;for Mounjaro and $1.9 billion&nbsp;for Zepbound.
During the conference, David Ricks outlined two reasons for the guidance update:
<ul>
<li>The diabetes GLP market, in December, outperforms the rest of the quarter and in year this did not happen&#8230;The CEO said this could be just a guess. The company said it did not predict it. "This year that didn't happen in GLP-1," said Ricks, who speculated that changes in Medicare Part D and insurance edits have prevented patients from doubling up their prescriptions at the end of the year to avoid deductible costs early in the following year."</li>
<li>Stocking levels were a big discussion during Q3 results. The company dropped about 8 selling days in that quarter alone. The company expected a buildback at the end of the year because every year, a couple of days of buildback happen, and it did not happen this year.</li>
</ul>
Regarding the guidance approach, the CEO noted, "The scale of this business and the way it's been growing, the consumer part of it, along with the stocking dynamics, it's just been a learning [experience] for us," Ricks said. "Our forecasters really nailed the rest of the portfolio. We don't have a problem with forecasting. It's just, this market is quite different."
Goldman analyst Chris Shibutani writes, "We expect this preliminary 4Q results to heighten concerns relating to underlying demand dynamics, which initially emerged at a broader level amongst investors during the 3Q results and guidance update."
Price Action: LLY stock is up 0.59% at $749.28 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/43004444/intel-plans-to-spin-off-5-billion-venture-capital-segment-will-remain-anchor-investor" target="_blank" rel="noreferrer noopener">Intel Plans To Spin Off $5 Billion Venture Capital Segment, Will Remain Anchor Investor</a></li>
</ul>
Photo via Eli Lilly and Company

Large Cap

Guidance

Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall

BIO-Key International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) shares are moving higher on Wednesday after the company announced that the National Bank of Egypt is <a href="https://www.benzinga.com//node/43000097">deploying its PortalGuard platform</a>. 
The Details: The deployment of BIO-Key&#8217;s PortalGuard will secure access to the bank&#8217;s applications by leveraging PortalGuard&#8217;s advanced Multi-Factor Authentication and Single Sign-On capabilities.
The implementation of PortalGuard is being done in collaboration with Raya Information Technology. Raya will manage the deployment and coordinate technology vendor resources to implement the process smoothly.
&#8220;By securing all access points with multi-factor authentication and eliminating the need for multiple credentials, NBE can now provide employees with Single Sign-On access to all their applications,&#8221; said Alex Rocha, Managing Director BIO-key EMEA. 
The company said its next goal is to deliver PortalGuard's capabilities to millions of consumers and businesses.
Nicholas Prinz, Regional Director, Middle East and Africa at BIO-key, said &#8220;This project highlights the growing need for advanced identity solutions in the Middle East and Africa. We are proud to collaborate with Raya Information Technology to deliver cutting-edge solutions that meet the demands of such a prestigious institution as the National Bank of Egypt.&#8221;&nbsp;
Related Link: <a href="https://www.benzinga.com/insights/options/25/01/43012229/decoding-visas-options-activity-whats-the-big-picture">Decoding Visa&#8217;s Options Activity: What&#8217;s the Big Picture?</a>
BKYI Price Action: At the time of writing, BIO-Key stock is trading 56.2% higher at $2.14, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Via Shutterstock

BKYI

What's Going On With BIO-Key International Stock Wednesday?

Morpheus, a platform focused on launching Smart Agents, has introduced a $10 million rewards program in its native MOR token specifically designed for its community of builders.
This initiative, which went live on the Base network, follows a similar rewards program for AI Compute Providers, a step forward in Morpheus&#8217; ongoing strategy to develop an economic ecosystem for decentralized AI.
The move is aimed at attracting developers to build and contribute to the platform, particularly in the rapidly growing field of AI agents.
The builder rewards program incentivizes developers to create various components for the Morpheus platform, including Smart Agents themselves, user interfaces, decentralized applications (dApps), and other tools. 
This structure is intended to encourage a vibrant and multifaceted ecosystem that supports all aspects of agent creation and deployment. 
Morpheus is positioning itself as an all-in-one platform, emphasizing its ability to offer developers access to funding, computation, and streamlined agent deployment, aiming to provide an advantage over other projects that only focus on a single area.
Central to Morpheus&#8217; system is its four-pronged approach, which recognizes contributions from code, capital, compute and builders.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43008666/sec-under-trump-administration-to-revise-crypto-policies-report">SEC Under Trump Administration To Revise Crypto Policies: Report</a>
The rewards system seeks to compensate all participants equitably in MOR tokens, promoting a self-sustaining ecosystem. 
Moreover, holders of the MOR token are entitled to a share of the network's compute power, allowing agents continuous access to resources. 
The tokenomics of the network is designed to support the development of decentralized AI applications, with the long term goal of fostering a broad community around the project.
According to Morpheus open-source contributor David Johnston, this launch positions Morpheus at the forefront of the current AI agent expansion, welcoming agents from diverse chains and frameworks. 
This is intended to be a move towards a more universal platform for AI agent creation. 
The underlying incentive is that this allows compute and builder tokenomics to work together efficiently to reward developers fairly and in a permissionless fashion.
Morpheus operates as a decentralized AI network that optimizes the use of computational power. 
It offers users a ChatGPT-like interface that allows interaction via decentralized data routing. 
The network also provides access to personal AIs, facilitates crypto payments for AI services, features an AI marketplace, and allows for generating images via multiple Large Language Models (LLMs). 
The platform is supported by an open-source community, as well as partnerships with projects like Lumerin. 
The core of the offering is that it provides a wide ranging set of tools to work within this decentralized AI ecosystem.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43008361/dubai-announces-crypto-tower-to-host-blockchain-businesses">Dubai Announces &#8216;Crypto Tower&#8217; To Host Blockchain Businesses</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Morpheus Incentivizes AI Agent Development With $10M Builder Rewards

Wells Fargo analyst Roger Read maintains BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) with a Equal-Weight and lowers the price target from $31 to $30.

Price Target

Wells Fargo Maintains Equal-Weight on BP, Lowers Price Target to $30

In the current market session, MGM Resorts Intl Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) price is at $33.75, after a 1.96% spike. However, over the past month, the stock decreased by 1.66%, and in the past year, by 22.45%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1736968542_0.png" alt="Past Year Chart" />

<h3>MGM Resorts Intl P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 80.1 in the Hotels, Restaurants &amp; Leisure industry, MGM Resorts Intl Inc. has a lower P/E ratio of 11.86. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1736968542_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for MGM Resorts Intl

Zelman &amp; Assoc initiates coverage on Cavco Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) with a Outperform rating.

Initiation

CVCO

Zelman & Assoc Initiates Coverage On Cavco Indus with Outperform Rating

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 gaining over 100 points on Wednesday.
The Dow traded up 1.69% to 43,237.93 while the NASDAQ rose 2.35% to 19,491.49. The S&amp;P 500 also rose, gaining, 1.80% to 5,947.81.
Check This Out: <a href="https://www.benzinga.com/25/01/42998360/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Communication services shares surged by 2.4% on Tuesday.
In trading on Tuesday, consumer staples shares fell by 0.1%.
Top Headline
JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported upbeat fourth-quarter FY24 results.
Reported revenue rose 11% year-on-year to $42.8 billion. Net revenue (managed) was $43.7 billion (+10% Y/Y), beating the consensus of $41.707 billion. EPS of $4.81 exceeded the consensus of $4.11.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares shot up 106% to $1.11. Safe &amp; Green Holdings announced the execution of a binding Letter of Intent to acquire 100% of the outstanding securities of New Asia Holdings Inc.</li>
<li>Shares of Vision Marine Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>)got a boost, surging 29% to $1.80 after the company announced it filed its latest patent application with the United States Patent and Trademark Office for a Battery Authentication Encryption Technology.</li>
<li>Compass Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) shares were also up, gaining 18% to $6.62 after the company raised its FY24 guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Keros Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) shares dropped 17% to $10.32 after the company announced an update on its Phase 2 TROPOS trial and halted all dosing based on the ongoing safety review.</li>
<li>Shares of Aclarion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) were down 59% to $0.040 after the company reported the pricing of $14.4m public offering of common stock and warrants.</li>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) was down, falling 40% to $0.25 after the company announced the pricing of a $1.5 million public offering.</li>
</ul>
Commodities In commodity news, oil traded up 2.8% to $79.69 while gold traded up 1.3% at $2,716.20.
Silver traded up 3.8% to $31.505 on Wednesday, while copper rose 1% to $4.3855.
Euro zone
European shares closed higher today. The eurozone's STOXX 600 surged 1.33%, Germany's DAX 40 gained 1.50% and France's CAC 40 gained 0.69%. Spain's IBEX 35 Index gained 1.25%, while London's FTSE 100 gained 1.21%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 falling 0.08%, China's Shanghai Composite Index declining 0.43%, Hong Kong's Hang Seng Index gaining 0.34% and India's BSE Sensex rising 0.29%.
Economics
<ul>
<li>The headline Consumer Price Index rose 2.9% year-over-year in December, according to Wednesday's data from the Bureau of Labor Statistics.</li>
<li>The EIA said crude inventories declined by 1.961 million barrels last week, compared to market estimates of a 1.6 million-barrel draw.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42997542/top-3-tech-and-telecom-stocks-that-may-explode-this-quarter">Top 3 Tech And Telecom Stocks That May Explode This Quarter</a></li>
</ul>

Earnings

Eurozone

Commodities

ACON

COMP

KROS

Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views

In conjunction with the 2025 J.P. Morgan Healthcare Conference, the analyst hosted an investor lunch with Ultragenyx Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>).
The analyst <a href="https://www.benzinga.com/quote/RARE/analyst-ratings" target="_blank" rel="noreferrer noopener">keeps an Overweight rating</a> on Ultragenyx with a price target of $102 and says the company is uniquely positioned in the long term with an expansive and diverse pipeline of orphan disease assets and highly regarded management. JP Morgan sees multiple value-creating catalysts over the next six to 18 months.
<ul>
<li>Ultragenyx&#8217;s recent meeting focused on setrusumab and the ongoing Phase 3 ORBIT trial. The analyst noted that the company remains confident in the trial&#8217;s success, with a second interim analysis expected by mid-2025 and final results by the end of 2025.</li>
<li>At current share levels, the analyst noted the market is not fully valuing the setrusumab program and anticipates positive trial data could push Ultragenyx stock price to a ~$7-handle.</li>
<li>Ultragenyx emphasized that moving forward to the second interim analysis does not change the study&#8217;s likelihood of success. Instead, the additional time allows for clearer differentiation between the setrusumab and placebo groups, with the minimum follow-up increasing from 7 months in the first interim analysis to 12 months in the second.</li>
<li>On the commercial front, Ultragenyx plans to leverage its existing Crysvita infrastructure in the U.S. for setrusumab, given overlapping call points.</li>
<li>Approval could also make the company eligible for a Priority Review Voucher, providing a potential source of non-dilutive capital. In Europe, where Mereo owns the rights, Ultragenyx will lead the regulatory filing process and anticipates submitting around 2-3 months after the U.S. filing.</li>
</ul>
On Sunday, Ultragenyx reported preliminary 2024 revenue of $555 million—$560 million, compared to the consensus of $543.02 million.
Crysvita&#8217;s revenue for 2024 is estimated to be $405 million—$410 million, and Dojolvi&#8217;s revenue is estimated to be $87 million—$89 million.
The company expects 2025 sales of $640 million—$670 million versus a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42935224/ultragenyx-reports-preliminary-2024-revenue-financial-guidance-for-2025-pipeline-updates-and-2025-" rel="noreferrer noopener">consensus of $648.54 million</a>.
Price Action: RARE stock is up 4.31% at $41.75 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/01/43003727/microsoft-to-cut-costs-pause-hiring-in-us-consulting-tighten-spending" target="_blank" rel="noreferrer noopener">Microsoft To Cut Costs, Pause Hiring In US Consulting, Tighten Spending</a></li>
</ul>
Photo via Shutterstock.

RARE

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside

Zelman &amp; Assoc initiates coverage on Champion Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKY#NYSE">SKY</a>) with a Underperform rating.

Zelman & Assoc Initiates Coverage On Champion Homes with Underperform Rating

Whales with a lot of money to spend have taken a noticeably bullish stance on BP.
Looking at options history for BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 75% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $297,520 and 3, calls, for a total amount of $111,420.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $29.0 to $37.0 for BP over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for BP's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across BP's significant trades, within a strike price range of $29.0 to $37.0, over the past month.
<h3>BP 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736967680_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$7.0</td>
<td>$6.9</td>
<td>$6.9</td>
<td>$37.00</td>
<td>$133.8K</td>
<td>688</td>
<td align="right">194</td>
</tr>
<tr>
<td>BP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.13</td>
<td>$1.09</td>
<td>$1.13</td>
<td>$30.00</td>
<td>$56.5K</td>
<td>3.4K</td>
<td align="right">501</td>
</tr>
<tr>
<td>BP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.28</td>
<td>$1.22</td>
<td>$1.24</td>
<td>$32.00</td>
<td>$55.8K</td>
<td>12.4K</td>
<td align="right">450</td>
</tr>
<tr>
<td>BP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.42</td>
<td>$1.37</td>
<td>$1.37</td>
<td>$29.00</td>
<td>$46.8K</td>
<td>2.8K</td>
<td align="right">342</td>
</tr>
<tr>
<td>BP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.97</td>
<td>$0.93</td>
<td>$0.93</td>
<td>$29.00</td>
<td>$31.8K</td>
<td>3.7K</td>
<td align="right">342</td>
</tr>
</tbody>
</table>

<h3>About BP</h3>
BP is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 1.1 million barrels of liquids and 6.9 billion cubic feet of natural gas per day. At the end of 2023, reserves stood at 6.8 billion barrels of oil equivalent, 55% of which are liquids. The company operates refineries with a capacity of 1.6 million barrels of oil per day.
Following our analysis of the options activities associated with BP, we pivot to a closer look at the company's own performance.
<h3>Current Position of BP</h3>
<ul>
<li>With a trading volume of 7,053,729, the price of BP is up by 0.16%, reaching $31.14.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 20 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for BP, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

BP Unusual Options Activity For January 15

Investors with a lot of money to spend have taken a bearish stance on Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with INTC, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Intel.
This isn't normal.
The overall sentiment of these big-money traders is split between 33% bullish and 53%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $1,287,568, and 7 are calls, for a total amount of $322,067.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $30.0 for Intel over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Intel's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Intel's substantial trades, within a strike price spectrum from $13.0 to $30.0 over the preceding 30 days.
<h3>Intel Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736967675_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.79</td>
<td>$2.69</td>
<td>$2.71</td>
<td>$18.00</td>
<td>$818.4K</td>
<td>42.6K</td>
<td>3.0K</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$9.45</td>
<td>$9.4</td>
<td>$9.45</td>
<td>$28.00</td>
<td>$113.4K</td>
<td>9.1K</td>
<td>120</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.55</td>
<td>$4.5</td>
<td>$4.55</td>
<td>$24.00</td>
<td>$91.0K</td>
<td>14.5K</td>
<td>225</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$7.15</td>
<td>$7.0</td>
<td>$7.08</td>
<td>$25.00</td>
<td>$84.9K</td>
<td>23.2K</td>
<td>120</td>
</tr>
<tr>
<td>INTC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$2.63</td>
<td>$2.58</td>
<td>$2.63</td>
<td>$18.00</td>
<td>$71.5K</td>
<td>9.7K</td>
<td>275</td>
</tr>
</tbody>
</table>

<h3>About Intel</h3>
Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and was the prime proponent of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel has also been expanding into new adjacencies, such as communications infrastructure, automotive, and the Internet of Things. Further, Intel expects to leverage its chip manufacturing capabilities into an outsourced foundry model where it constructs chips for others.
After a thorough review of the options trading surrounding Intel, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Intel</h3>
<ul>
<li>Currently trading with a volume of 27,088,792, the INTC's price is up by 1.61%, now at $19.51. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 15 days.</li>
</ul>
<h3>What Analysts Are Saying About Intel</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $21.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Neutral rating on Intel with a target price of $21. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Intel, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

INTC

What the Options Market Tells Us About Intel

7 analysts have shared their evaluations of Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $20.0, a high estimate of $20.00, and a low estimate of $20.00. Staying constant with the previous average price target, the current average remains unchanged. 
<img src="https://www.benzinga.com/files/images/story/2025/1736967672_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Lands' End's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lands' End. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lands' End compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Lands' End's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Lands' End's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lands' End analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Lands' End Better</h2>
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.
<h3>Breaking Down Lands' End's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Lands' End's revenue growth over 3 months faced difficulties. As of 31 October, 2024, the company experienced a decline of approximately -1.88%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Lands' End's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -0.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Lands' End's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -0.26%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Lands' End's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.07%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Lands' End's debt-to-equity ratio is below the industry average at 1.46, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Lands' End: 7 Analysts Share Their Views

Financial giants have made a conspicuous bearish move on Mobileye Global. Our analysis of options history for Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) revealed 8 unusual trades.
Delving into the details, we found 12% of traders were bullish, while 87% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $138,416, and 5 were calls, valued at $189,038.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $17.0 for Mobileye Global over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Mobileye Global stands at 1819.5, with a total volume reaching 7,722.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Mobileye Global, situated within the strike price corridor from $15.0 to $17.0, throughout the last 30 days.
<h3>Mobileye Global Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736967670_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$3.95</td>
<td>$17.00</td>
<td>$63.2K</td>
<td>63</td>
<td>926</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.75</td>
<td>$1.71</td>
<td>$1.75</td>
<td>$15.00</td>
<td>$52.5K</td>
<td>6.3K</td>
<td>419</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.1</td>
<td>$4.05</td>
<td>$4.05</td>
<td>$17.00</td>
<td>$44.5K</td>
<td>557</td>
<td>890</td>
</tr>
<tr>
<td>MBLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$17.00</td>
<td>$43.6K</td>
<td>63</td>
<td>1.2K</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$4.0</td>
<td>$3.95</td>
<td>$3.95</td>
<td>$17.00</td>
<td>$33.1K</td>
<td>557</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Mobileye Global</h3>
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. Mobileye is the Company's only reportable operating segment. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System &amp; Vehicles. It also provides data services to Expedite Maintenance Operations with AI-Powered Road Survey Technology.
Following our analysis of the options activities associated with Mobileye Global, we pivot to a closer look at the company's own performance.
<h3>Current Position of Mobileye Global</h3>
<ul>
<li>With a volume of 3,222,522, the price of MBLY is up 2.73% at $16.57. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 15 days.</li>
</ul>
<h3>Professional Analyst Ratings for Mobileye Global</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $23.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Loop Capital has decided to maintain their Buy rating on Mobileye Global, which currently sits at a price target of $23. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Mobileye Global, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MBLY

A Closer Look at Mobileye Global's Options Market Dynamics

Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $58.25, with a high estimate of $60.00 and a low estimate of $55.00. Witnessing a positive shift, the current average has risen by 11.48% from the previous average price target of $52.25.
<img src="https://www.benzinga.com/files/images/story/2025/1736967664_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Chefs' Warehouse among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andy Barish</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Alexander Slagle</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Ben Klieve</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Chefs' Warehouse. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Chefs' Warehouse compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Chefs' Warehouse's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Chefs' Warehouse's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CHEF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Chefs' Warehouse analyst ratings.</a>
<h2>Delving into Chefs' Warehouse's Background</h2>
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. The Chefs' Warehouse operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, mid and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos and speciality food stores.
<h3>Chefs' Warehouse's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Chefs' Warehouse showcased positive performance, achieving a revenue growth rate of 5.63% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.51%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.99%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Chefs' Warehouse's ROA excels beyond industry benchmarks, reaching 0.81%. This signifies efficient management of assets and strong financial health.
Debt Management: Chefs' Warehouse's debt-to-equity ratio stands notably higher than the industry average, reaching 1.93. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHEF

Assessing Chefs' Warehouse: Insights From 4 Financial Analysts

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ORKA stock, giving a Buy rating today. Sam Slutsky's rating is based on ...

Strong Growth Potential for Oruka Therapeutics Driven by Robust Financials and Promising Drug Pipeline

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report), with a price t...

Positive Outlook for Oruka Therapeutics Driven by Innovative Pipeline and Financial Stability

Jefferies analyst Michael Yee has maintained their bullish stance on ORKA stock, giving a Buy rating today. Michael Yee has given his Buy rating du...

Oruka Therapeutics' Promising Long-Term Strategy and Advancements in Psoriasis Treatments Drive Buy Rating

Wedbush analyst David Nierengarten initiated coverage with a Buy rating on Oruka Therapeutics (ORKA – Research Report) today and set a price target...

Wedbush Initiates a Buy Rating on Oruka Therapeutics (ORKA)

Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Oruka Therapeutics (ORKA – Research Report). The associated price ta...

Oruka Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating with $45 Target Price

Oruka Therapeutics, Inc. ( ($ORKA) ) has released its Q3 earnings. Here is a breakdown of the information Oruka Therapeutics, Inc. presented to its...

Oruka Therapeutics: Strong Q3 and Strategic Advances

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at $41...

Promising Potential of Oruka Therapeutics' ORKA-001 in Psoriasis Treatment

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today. The company's shares closed yesterda...

Oruka Therapeutics (ORKA) Gets a Buy from TD Cowen

Oruka Therapeutics (ORKA) announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company's novel...

Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), Vertex ...

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)

APLT

VRTX

Press Releases

Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001's Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19

Comments

Oruka Therapeutics

Noticias

Últimas noticias sobre Oruka Therapeutics (NASDAQ:ORKA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL